Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study

Mona Mohammed Abdelrahman | Noha Mohammed Abd-Elrahman | Tasneem Mohammed Bakheet

Abstract
With the number of coronavirus disease 2019 (COVID-19) infected patients increasing all over the world, a large number of survivors have reported changes in their quality of life or experienced re-infection. So, we aimed to detect the percentage, type, and risk factors of persistent symptoms after improvement from acute COVID-19 infection and to detect the percentage of COVID-19 re-infection and degree of severity of the second infection. One hundred seventy-two (59 male, 113 female) patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were followed up via mobile phone every 2 months for 8 to 10 months. After recovery, 105 patients (61%) (30 male, 75 female) reported one or more COVID-19 persistent symptoms. Fatigue, dyspnea, and depression were the most common persistent symptoms representing 37.3%, 22%, 22%, respectively. We found that age was independently related to the persistence of symptoms. During the follow-up, six females (3.5%) had laboratory-confirmed COVID-19 re-infection. Their mean age was 35.7 ± 11 years. The mean interval from the complete recovery of the first infection to the onset of the second one was 53 ± 22.2 days and ranged from 30 to 90 days. The second infection was milder in severity than the first infection in 83.33% of cases. There was a high percentage of patients who complained of persistent symptoms after recovery from COVID-19. Fatigue and headache were the most common persistent symptoms. Age was considered a risk factor for persistent symptoms. Re-infection with SARS-CoV-2 can occur after recovery.

KEYWORDS
COVID-19, persistent symptoms, re-infection, risk factors, SARS-CoV-2

1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19) infection has been spread rapidly all over the world, affecting millions of patients over the last few months. COVID-19 illness has a wide range of symptoms from mild disease to severe one. Fever, cough, dyspnea, and fatigue are the most commonly reported symptoms of COVID-19 illness. The course of illness ranges from 2 weeks for a mild illness to 3-6 weeks for those with a severe or critical illness.

Numerous studies have reported that one or more symptoms of COVID-19 persist for more than a month after recovery. Fatigue and dyspnea have been reported as the most common persistent complaints after recovery from COVID-19. Several studies have indicated that the persistence of symptoms is not linked to a certain age, gender, or severity of the disease. However, another study noticed those elderly patients and those with chronic health issues were associated with higher percentages of persistent symptoms.
Re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported in several studies. The severity of the second attack varies over all the studies. Prado-Vivar et al. reported that the second infection is more severe than the first one while Chen et al. documented that 75% of patients with re-infection were asymptomatic.

So, we aimed to detect the percentage, type, and risk factors of persistent symptoms after improvement from acute COVID-19 infection and to detect the percentage of COVID-19 re-infection and degree of severity of the second infection.

2 | PATIENTS AND METHODS

Out of 250 patients who tested positive for SARS-CoV-2 in Sohag University COVID-19 isolation hospital during the period from 15th May 2020 to 25th July 2020, 172 (59 male, 113 female) patients improved and agreed to be recruited in the present study. Their age range was 17–80 years. Of them, 22 patients needed hospital admission in Sohag University COVID-19 isolation department and 150 patients received treatment in home isolation. The severity of COVID-19 infection was evaluated according to the COVID-19 management protocol of the Ministry of Health, Egypt. Patient improvement and discharge criteria included 10 days from symptom onset in addition to 3 days free of fever and respiratory symptoms. Patients with severe complex illness, pregnant or lactating females, and patients who refused to participate or give a complete detailed history were excluded from the study. The study protocol was approved by Sohag University Ethical Committee for medical research with the registration number (Soh-Med-21-2-46).

The baseline data was collected from the Sohag University isolation hospital of COVID-19, then, the researchers conducted interviews with all participants through the mobile phone after the improvement of acute COVID-19. After that, we followed the patients up through mobile phones every 2 months for 8–10 months.

Informed consent was taken from all participants. Then, the researchers asked about demographic criteria, current chronic medical diseases, the presentation of COVID-19 at the test time, whether these symptoms improved by the interview time, and whether the patients had reverted to their normal health status at the interview date and during follow up. Any residual or newly reported symptoms not related to previous illness or underlying chronic medical condition was considered as persistent symptoms of COVID-19 infection. A complete detailed history was taken for the reported persistent symptoms. We also asked if there was a re-infection with COVID-19 and the interval between the first and second infection.

3 | STATISTICAL ANALYSIS

Data were analyzed using SPSS version 25. Continuous variables were analyzed as mean ± SD when normally distributed or as median (interquartile range) when not normally distributed. Categorical variables were represented as a number (%). \( \chi^2 \) tests were used to compare differences between the two groups. Multivariate logistic regression analysis was used to detect the potential risk factors associated with the persistence of symptoms.

4 | RESULTS

From May 2020 to March 2021, 172 COVID-19 infected patients participated in our study and were followed up for 8 to 10 months. The principal characteristics of the participants and their clinical parameters are shown in Table 1. Twenty-two positive cases were hospitalized (12.8% of COVID-19 cases), seven of them were admitted to the intensive care unit (31.8% of hospitalized patients and about 4% of COVID-19 cases).

The median duration of COVID-19 infection was 15 days and the interquartile range was 10–21 days. The clinical presentation of acute COVID-19 infection in our patients involved multiple systems, however, generalized malaise, fever, headache, and cough were the most common presenting symptoms as shown in Figure 1.

| Parameters | COVID-19 positive cases, N = 172 |
|------------|--------------------------------|
| No. (%)    |                                |
| Age        | Mean ± SD 41.8+ 17.6            |
| Sex        | Male 59 34.3%                   |
|            | Female 113 65.7%                |
| Residence  | Urban 71 41.3%                  |
|            | Semi-urban 57 33.1%             |
|            | Rural 44 25.6%                  |
| Occupation | Physicians 47 27.3%             |
|            | Working in medical field; not physicians 21 12.2% |
|            | Not working in medical field 30 17.4% |
|            | Not working 74 43.0%            |
| Smoking    | Active smoker 6 3.5%            |
|            | Non smoking 151 87.8%           |
|            | X-smoker 15 8.7%                |
| Comorbid diseases | Diabetes mellitus 24 13.9% |
|            | Hypertension 37 21.5%           |
|            | Chronic obstructive lung diseases 10 5.8% |
|            | Chronic renal failure 4 2.3%    |
|            | Ischemic heart disease 12 7%    |
|            | Others 10 5.8%                  |

Abbreviation: COVID-19, coronavirus disease 2019.
After recovery, 105 patients (61%) (30 male, 75 female) reported one or more persistent COVID-19 symptoms. The median duration of persistent symptoms was 30 days with a range of 10–120 a day. Twenty-two patients (12.8%) reported one persistent complaint, 24 patients (14%) reported two persistent complaints, and 59 patients (34.3%) reported three or more persistent complaints. Impairment of quality of life was noticed in 41.9% of patients.

Fatigue, dyspnea, and depression were the most common persistent symptoms representing 37.3%, 22%, 22% respectively. This was followed by insomnia (13.4%), joint pain (12.2%), headache (10.5%), alopecia (10.5%), forgetting (9.9%), dry cough (8.1%), and chest pain (7.6%). The authors found that fatigue, joint pain, and headache were the most common persistent general manifestations. As regards the respiratory system, we noticed that dyspnea, dry cough, and chest pain were the most frequent persistent complaint. Loss of smell and taste were the most frequent persistent gastrointestinal complaints. Depression and insomnia were the most frequently reported persistent neurological complaints (Table 2).

During follow-up, newly emerged symptoms, such as disorientation, forgetting, and alopecia were reported in 11%, 9.9%, and 10.5% of our patients, respectively (Table 3).

In assessing risk factors for persistent symptoms, the researchers found that age was independently related to the persistence of symptoms. The severity of illness, sex, and co-morbidity were not risk factors for the persistence of symptoms (Table 4).

During the follow-up, six females (3.5%) had laboratory-confirmed COVID-19 re-infection. Their mean age was 35.7 ± 11 years. The mean interval from the complete recovery of the first infection to the onset of the second one was 53 ± 22.2 days with a range from 30 to 90 days. The second infection was milder in severity than the first infection, in 83.33% of cases.

5 | DISCUSSION

In the present study, after recovery, 61% of patients reported one or more persistent COVID-19 symptoms. Similarly, the percentage of persistent symptoms in previous studies among SARS-CoV-2 positive patients ranged from 35% to 89.2%.2–14 In our research, 22 patients (12.8%) reported one persistent complaint, 24 patients (14%) reported two persistent complaints, and 59 patients (34.3%) reported three or more persistent complaints. These results were in concordance with Carfi et al.,10 and Rosales-Castillo et al. findings.

Fatigue and dyspnea was the most common persistent symptoms in our patient. Similar results were noticed in several previous research.4,10,11,15–17 The pathogenesis of persistent symptoms is not well known; however, multiple theories have been postulated. It may be due to the direct effect of the virus, immune reaction, and loneliness.14 Bornstein et al. indicated that antibodies against β-adrenergic and muscarinic receptors due to viral or autoimmune etiology might be a cause for persistence of symptoms. Residual inflammation, organ injury, the nonspecific impact of the hospital admission or mechanical ventilation, or the effect on pre-existing health issues could all be risk factors for the persistence of symptoms.1 Yong supposes that SARS-CoV-2 invasion of the brain stem plays a major role in the persistence of symptoms and could explain multiple systems’ involvements as the brain stem controls the functions of several organs.2
In assessing risk factors for persistent symptoms, the authors found that old age was independently related to the persistence of symptoms. The severity of illness, sex, and comorbidities are not risk factors for the persistence of symptoms. However, Kamal et al.\(^4\) reported that severity of illness and co-morbid diseases are risk factors for the persistence of symptoms. Although Huang et al.\(^16\) reported that the severity of illness and female sex are risk factors for persistent symptoms. Tenforde et al.\(^12\) documented that age more than 65 years and co-morbid diseases are risk factors of persistent symptoms. Stavem et al.\(^13\) also showed that co-morbidities and the number of symptoms during acute COVID-19 are risk factors for the persistence of symptoms.

During the follow-up, six females (3.5%) had laboratory-confirmed COVID-19 re-infection. The mean interval from the complete recovery of the first infection to the onset of the second one was 53 ± 22.2 days with a range from 30 to 90 days. The second infection was milder in severity than the first infection in 83.33% of cases. Adrielle dos Santos et al.\(^19\) revealed that 90.9% of re-infection occurs among females with a time interval between first and second infection of 18–134 days. They also reported that the severity and frequency of symptoms were higher in the second attack.

### 6 | LIMITATIONS OF THE STUDY

The relatively small sample size, single-center study, and absence of direct contact and physical examination of the patients were the main limitations in the current study.

### 6.1 | Recommendation

Long-term follow-up of patients who have recovered from COVID-19 infection is recommended especially in the elderly.

### 7 | CONCLUSION

There is a high percentage of patients who complained of persistent symptoms after recovery from COVID-19. Fatigue and headache are the most common persistent symptoms. Age is considered a risk factor for the persistence of symptoms.
factor for persistent symptoms. Re-infection with SARS-CoV2 can occur after recovery.

ACKNOWLEDGMENTS
The authors would like to thank all health care workers and our patients who helped us in the collection of data. The authors state that they have no financial and personal relationships with other organizations or individuals that could have an undue effect on their work.

CONFLICT OF INTERESTS
The authors declare that there are no conflicts of interest.

DATA AVAILABILITY STATEMENT
Data of this study is available under request to the corresponding author.

ETHICAL STATEMENT
The study protocol was accepted by the Ethical Committee of Scientific Research, Faculty of Medicine, Sohag University. Protocol serial number: Soh-Med-21-02-46.

CLINICALTRIALS. GOV IDENTIFIER
NCT04764773.

ORCID
Mona Mohammed Abdelrahman http://orcid.org/0000-0002-8784-848X

REFERENCES
1. Moreno-Pérez O, Esperanza Merino J, Leon-Ramirez O-M, et al. Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. Journal of Infection. Published online. 2021. https://doi.org/10.1016/j.jinf.2021.01.004
2. Yong SJ. Persistent Brainstem Dysfunction in Long-COVID: A Hypothesis. ACS Chem Neurosci. 2021;12:573-580. https://doi.org/10.1021/acschemneuro.0c00793
3. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89-95. https://doi.org/10.1016/j.cmi.2020.09.023
4. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2020;75:1-5. https://doi.org/10.1111/ijcp.13746
5. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, et al. A case of SARS-CoV-2 reinfection in Ecuador. The Lancet Infectious Diseases. Published online. 2020;21:e142. https://doi.org/10.1016/S1473-3099(20)30910-5
6. Chen Z, Xie W, Gea Z, et al. Reactivation of SARS-CoV-2 infection following recovery from COVID-19 Zhihai. Journal of infection and Public Health. Published online. 2021;144034. https://doi.org/10.1016/j.jiph.2021.02.002
7. CDC Centers for Disease Control. Symptoms of Coronavirus | CDC. Centers For Disease Control and Prevention. 2019;2019:2019-2021. Accessed March 12, 2021. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
8. Masoud HH, Zaky S, Baki AA. Management protocol for COVID-19 patients version 1.4/30th May 2020 Ministry of Health and Population (MOHP). Egypt. 2020.
9. CDC. Interim guidance on duration of isolation and precautions for adults with COVID-19. Accessed March 19, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html
10. Carfi A, Bernabei R, Landi te CSG. Persistent symptoms in patients after acute COVID-19. N Engl J Med. 2020;324(6):603-606. https://doi.org/10.1056/nejmp2014836
11. Rosales-Castillo A, García de los Ríos C, Mediavilla García JD. Persistent symptoms after acute COVID-19 infection: importance of follow-up. Med Clin. 2021;156(1):35-36. https://doi.org/10.1016/j.medcli.2020.08.001
12. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among out-patients with COVID-19 in a Multistate Health Care Systems Network—United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993-998. https://doi.org/10.15585/mmwr.mm6930e1
13. Stavem K, Ghanima W, Olsen MK, Gilbøe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2020;0:1-3. https://doi.org/10.1136/thoraxjnl-2020-216377
14. Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324(17):1723-1724. https://doi.org/10.1001/jama.2020.19719
15. Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-0020. https://doi.org/10.1183/23120541.00542-2020
16. Godeau D, Petit A, Richard I, Roquelaure Y, Descatha A. 6 months after COVID-19 infection: importance of extra-corporeal apheresis? J Med Virol. 2021;93:1013-1022. https://doi.org/10.1002/jmv.27156
17. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93(2):1013-1022. https://doi.org/10.1002/jmv.26368
18. Bornstein SR, Voit-Bak K, Donate T, et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: is there a role for extracorporeal apheresis? Mol Psychiatry. 2021;12-15. https://doi.org/10.1038/s41380-021-01148-4
19. Adrielle dos Santos L, Filho P, Silva A, et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infect. 2021;82:1-8. https://doi.org/10.1016/j.jinf.2021.01.020

How to cite this article: Abdelrahman MM, Abd-Elrahman NM, Bakheet TM. Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study. J Med Virol. 2021;93:5942-5946. https://doi.org/10.1002/jmv.27156